Research & publications
Original research is at the heart of what we do. For more than 60 years, our experts have published across a wide range of topics from the fundamentals of health economics itself to the challenges facing health care in the UK and internationally.
The latest research and publications
The economic and health impact of UK CEiRSI: the UK Centre of Excellence for In-Silico Regulatory Science and Innovation
Investing in the UK Centre of Excellence for in-silico Regulatory Science & Innovation (CEiRSI) could accelerate the adoption of in-silico technologies in the UK. Doing so could improve patient access to innovation, reduce NHS costs and strengthen the UK’s position as a global leader in in- silico technology and life sciences.
Immunoglobulin sustainability in the United Kingdom
Our report, commissioned and funded by argenx, looks at the challenges to Ig sustainability and assesses four potential policy responses.
The economic burden of overweight and obesity in Europe
Effective obesity strategies require action across government and society, and a broader approach to evaluating their costs and benefits.
The economic burden of overweight and obesity in Europe
Effective obesity strategies require action across government and society, and a…
Unlocking the broader value of biologic therapies through biosimilar-enabled access and repositioning
Biologic medicines account for over 40% of global pharmaceutical spend. When…
Addressing the systemic challenges of underinvestment in prevention
Prevention of ill-health is an underexploited tool for protecting health systems…
The impact of inflation on incremental costs in HTA
Inflation reshapes the economic landscape in which new treatments are evaluated.…
The value of fast diagnostics in time-critical infections
Advancing earlier intervention in time‑critical infections Sepsis continues to…
Evaluating novel antimicrobials within EU joint clinical assessments
Antimicrobial resistance (AMR) is a growing global health and economic threat.…
The burden of LDL-cholesterol-driven atherosclerotic cardiovascular diseases
Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity…
The case for adopting a broader perspective on value in Health Technology Assessment
In this Whitepaper, we describe different perspectives that can be adopted in…
Novel devices: optimising drug delivery in multiple myeloma
Biologics: Driving innovation in the treatment of multiple myeloma Biological…
A global landscape analysis of access to tumour-agnostic therapies
Tumour-agnostic (TA) therapies represent a paradigm shift in oncology by…